STOCKS TELEGRAPH

Tag: Bone Biologics

  • Bone Biologics (BBLG) Stock Rallies Strongly In Pre-Hour Trading

    Bone Biologics (BBLG) Stock Rallies Strongly In Pre-Hour Trading

    During today’s pre-market session, shares of Bone Biologics Corporation (NASDAQ: BBLG) were showing a notable upward trend, rising 82.21% to $7.58 as of the last check. Significant business activities, including a significant patent application and an update on Nasdaq compliance, preceded the notable increase in BBLG’s stock value.

    A Patent Application Promotes Bone Treatment Innovation

    Bone Biologics (BBLG) has submitted a new patent application to the USPTO for its innovative NELL-1 protein technology. The application focuses on the potential therapeutic applications of recombinant human NELL-1 (rhNELL-1) polypeptide compositions to treat a variety of bone-related conditions.

    This scientific discovery represents a major turning point in Bone Biologics’ ongoing attempts to develop more potent treatments, particularly for patients having spinal fusion procedures. If granted, the patent will bolster BBLG’s intellectual property assets and long-term clinical development trajectory.

    Nasdaq Compliance Has Been Restored

    In a different statement, Bone Biologics stated that it is now in compliance with Listing Rule 5550(a)(2), which requires a minimum bid price, as required by the Nasdaq. The Nasdaq Stock Market LLC previously notified the business that its common stock now satisfies all requirements for continuing listing on the Nasdaq Capital Market.

    On April 7, 2025, Nasdaq first informed Bone Biologics that the firm was noncompliant after its shares had fallen below $1.00 per share for 30 straight working days. In order to fix this, BBLG has to keep the closing bid price at least $1.00 for ten consecutive trading sessions, a milestone Bone Biologics officially attained on June 24, 2025.

    Strategic Momentum and Investor Confidence

    Complete listing compliance and a possible patent filing are two events that show Bone Biologics’ strategic goals have advanced significantly. BBLG is positioned well within the biomedical innovation environment thanks to the notable stock rise, which reflects rising investor confidence in the company’s pipeline and operational prospects.

  • Bone Biologics Corp. (BBLG) stock Continues its Bullish Momentum into the After Hours

    On February 09, 2022, Bone Biologics Corp. (BBLG) stock added a good 19.59% during regular trading. The stock continued to rise in the after-hours to gain a further 7.85%. No official announcement or SEC filing is responsible for the bullish momentum of the stock.

    The medical device company’s stock had a value of $2.5592 per share at the close of the previous regular trading session. After adding a further $0.20 in the after-hours, BBLG stock reached a value of $2.7600 per share, on Wednesday.

    Founded in 2004, Bone Biologics Corp. has a market capitalization of $22.15 million. Currently, the company has 10.5 million shares outstanding in the market.

    BBLG stock Movement

    BBLG stock has been in an uptrend since Monday, thus marking today as the third consecutive day of its bullishness. There is no official announcement or SEC filing from the company to explain the bullish momentum. It seems the stock has been gaining on external factors like social media discussions and stock sentiment.

    The recent bullish momentum has led the stock to gain a good 21.87% in the past five days. Presently, BBLG stands at a yea to date loss of 27.30% while it declined by a huge 86.35% last year.

    Recent Participation

    Recently, the company participated in the H.C. Wainwright BioConnect Virtual Conference. BBLG’s president and chief executive officer, Jeffrey Frelick presented at the conference on January 10. The conference took place from January 10 to January 13, 2022.

    BBLG’s SEC Filings

    8-K Current Report

    On December 22, the company filed a current report on Form 8-K regarding the employment agreement of its CFO, Deina H. Walsh. As per the revised employment agreement, her employment with the company was changed from a specified period to at-will. Furthermore, the agreement stated her base salary as $200,000 with eligibility for an annual bonus of 25% of the base salary.

    Ms. Walsh has been serving as BBLG’s Chief Financial Officer since November 4, 2014.

    10-Q Quarterly Report

    On November 15, the company filed its financial results for the third quarter of 2021.

    In the third quarter of 2021, the company had a net loss of $509.3K against $394.0K in the year-ago quarter. Resultantly, the net loss per basic and diluted share was $0.17 and $0.14 in Q3 2021 and 2020, respectively.

    Moreover, BBLG had no revenues in the third quarter of 2021.

    Public Offering

    On October 18, the company announced the closing of its public offering of 1,510,455 securities units at $5.25 per unit. The total gross proceeds from the offering were $7.9 million less discounts and commissions.